For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
|Videos|March 26, 2014
Improving the Efficacy of Abiraterone
Author(s)James Mohler, MD
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses how his laboratory is working to improve the efficacy of abiraterone for the treatment of prostate cancer.
Advertisement
Clinical Pearls
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses how his laboratory is working to improve the efficacy of abiraterone for the treatment of prostate cancer.
- A better understanding of the last 2 steps of the backdoor pathway could lead to improved treatment as androgen synthesis inhibitors (abiraterone, TAK-700, and TOK-001) all work upstream, far from DHT
- Researchers are testing whether an attack next to the preferred androgen DHT will improve response to FDA-approved agents
- Androgen deprivation therapy may be more effective if DHT levels in the tissue are reduced to 0
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5